Corona Remedies IPO Subscription Status

As of December 10, 2025, the Corona Remedies IPO IPO has been subscribed 144.54 times overall. The IPO is fully subscribed with strong investor demand indicating extremely high interest.

The Corona Remedies IPO IPO subscription window was open from December 08, 2025 to December 10, 2025. Investors could apply for shares during this period through their demat account or ASBA facility.

The Corona Remedies IPO IPO has a price band of ₹1,008 to ₹1,062 per share. The lot size is 14 shares, which means retail investors need to apply for a minimum of 14 shares. The minimum investment required is ₹14,112 (at lower price) or ₹14,868 (at upper price).

The Qualified Institutional Buyers (QIB) category for Corona Remedies IPO IPO has been subscribed 293.80 times. QIBs were offered 1,221,729 shares in this IPO. QIB category includes foreign institutional investors (FIIs), domestic mutual funds, banks, insurance companies, and other qualified institutional investors. The strong QIB subscription indicates high institutional investor confidence in Corona Remedies IPO.

The Retail Individual Investors (RII) category for Corona Remedies IPO IPO has been subscribed 30.39 times. Retail investors were offered 2,139,573 shares in this IPO. Retail category includes individual investors applying for shares up to ₹2 lakh. The high retail subscription reflects strong interest from small investors in Corona Remedies IPO IPO.

The overall Non-Institutional Investors (NII) category has been subscribed 220.18 times. The NII category is further divided into bNII (bids above ₹10 lakh) with 246.67 times subscription and sNII (bids below ₹10 lakh) with 167.20 times subscription. NII category includes high net-worth individuals (HNIs) and corporate entities investing above ₹2 lakh. The subscription data helps analyze the interest level from high-value investors in Corona Remedies IPO IPO.

The basis of allotment date for Corona Remedies IPO IPO will be announced soon. You can check your allotment status by visiting the registrar's website (Bigshare Services Private Limited) and entering your PAN number, application number, or DP ID. Alternatively, you can check through your demat account or the stock exchange website (NSE/BSE).

The listing date for Corona Remedies IPO IPO will be announced after the basis of allotment is finalized. The shares will be listed on NSE,BSE. After listing, you can trade the shares through your demat account.

The subscription rate (also called subscription multiple) indicates how many times the IPO has been oversubscribed. For Corona Remedies IPO IPO, the current subscription of 144.54 times means investors have bid for 144.54 times the number of shares offered. Since the subscription is above 1×, the IPO is fully subscribed. The high subscription indicates strong investor demand for Corona Remedies IPO shares. Higher subscription rates generally suggest strong market interest, but may also reduce individual allotment probability.

Investment decisions should be based on your own research, risk appetite, and financial goals. The Corona Remedies IPO IPO has received 144.54 times subscription, indicating strong investor interest. Before investing, consider factors such as the company's business model, financial performance, industry outlook, price band valuation, and your investment objectives. It is recommended to consult with a financial advisor and read the Red Herring Prospectus (RHP) before making any investment decision. Past performance and subscription data are not indicative of future returns.